Mepolizumab for eosinophilic chronic obstructive pulmonary disease

Mepolizumab for eosinophilic chronic obstructive pulmonary disease

Patients with chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype may benefit from treatment with mepolizumab, a monoclonal antibody directed against interleukin-5.We performed two phase 3, randomized, placebo-controlled, double-blind, parallel-group trials comparing mepolizu...

Detaylı Bibliyografya
Asıl Yazarlar:	Pavord, I, Chanez, P, Criner, G, Kerstjens, H, Korn, S, Lugogo, N, Martinot, J, Sagara, H, Albers, F, Bradford, E, Harris, S, Mayer, B, Rubin, D, Yancey, S, Sciurba, F
Materyal Türü:	Journal article
Dil:	English
Baskı/Yayın Bilgisi:	Massachusetts Medical Society 2017

Benzer Materyaller

Late breaking abstract - Dose-ranging study of mepolizumab in eosinophilic COPD
Yazar:: Pavord, I, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of METREX and METREO Exacerbation Endpoints
Yazar:: Bafadhel, M, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Mepolizumab for eosinophilic COPD
Yazar:: Sciurba, F, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of METREX and METREO Patient-Reported Outcomes, Response to Therapy and Lung Function
Yazar:: Chapman, K, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
Yazar:: Gunsoy, N, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Mepolizumab treatment in patients with severe eosinophilic asthma.
Yazar:: Ortega, H, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Glucocorticoids and mepolizumab in eosinophilic asthma.
Yazar:: Bel, E, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma
Yazar:: Shrimanker, R, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease
Yazar:: Mkorombindo T, ve diğerleri
Baskı/Yayın Bilgisi: (2019-08-01)

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.
Yazar:: Pavord, I, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
Yazar:: Bel, E, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
Yazar:: Steven W. Yancey, ve diğerleri
Baskı/Yayın Bilgisi: (2019-09-01)

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Yazar:: Ortega, H, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma
Yazar:: Yancey, S, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Mepolizumab in refractory eosinophilic asthma.
Yazar:: Pavord, I, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Mepolizumab, quality of life, and severe eosinophilic asthma.
Yazar:: Pavord, I
Baskı/Yayın Bilgisi: (2017)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
Yazar:: Howell, I, ve diğerleri
Baskı/Yayın Bilgisi: (2024)

Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes
Yazar:: Prazma CM, ve diğerleri
Baskı/Yayın Bilgisi: (2021-06-01)

Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab
Yazar:: Ian D. Pavord, ve diğerleri
Baskı/Yayın Bilgisi: (2022-05-01)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
Yazar:: Imran Howell, ve diğerleri
Baskı/Yayın Bilgisi: (2024-07-01)

Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma
Yazar:: Terufumi Shimoda, ve diğerleri
Baskı/Yayın Bilgisi: (2017-07-01)

Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis
Yazar:: Wechsler, M, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma
Yazar:: Moran, AM, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Mepolizumab and exacerbations of refractory eosinophilic asthma.
Yazar:: Haldar, P, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

Response to mepolizumab treatment is sustained across 4-weekly dosing periods
Yazar:: Ian D. Pavord, ve diğerleri
Baskı/Yayın Bilgisi: (2020-09-01)

Efficacy and safety of mepolizumab in Korean patients with severe eosinophilic asthma from the DREAM and MENSA studies
Yazar:: Mi-Kyeong Kim, ve diğerleri
Baskı/Yayın Bilgisi: (2021-03-01)

Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA
Yazar:: Frank C. Albers, ve diğerleri
Baskı/Yayın Bilgisi: (2019-07-01)

Treatment of eosinophilic myositis with mepolizumab
Yazar:: Saadia Waheed, ve diğerleri
Baskı/Yayın Bilgisi: (2018-01-01)

GLUCOLD, eosinophils and chronic obstructive pulmonary disease
Yazar:: Pavord, I
Baskı/Yayın Bilgisi: (2018)

Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
Yazar:: Shrimanker, R, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Biomarkers for severe eosinophilic asthma.
Yazar:: Yancey, S, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
Yazar:: Menzella F, ve diğerleri
Baskı/Yayın Bilgisi: (2016-06-01)

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
Yazar:: Shrimanker, R, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma
Yazar:: Moran, A, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Clinical Benefit of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis for Patients With and Without a Vasculitic Phenotype
Yazar:: Benjamin Terrier, ve diğerleri
Baskı/Yayın Bilgisi: (2023-07-01)

Blood eosinophil phenotype during treatment with mepolizumab in patients with severe eosinophilic asthma
Yazar:: Chio Sakai, ve diğerleri
Baskı/Yayın Bilgisi: (2024-07-01)

Mepolizumab-responsive recurrent eosinophilic eruption without peripheral eosinophilia
Yazar:: Nina B. Curkovic, MD, ve diğerleri
Baskı/Yayın Bilgisi: (2024-11-01)

Safety and Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis
Yazar:: Ravi Ranjan Pradhan, ve diğerleri
Baskı/Yayın Bilgisi: (2019-01-01)

Effectiveness of mepolizumab for eosinophilic pneumonia following bronchial thermoplasty
Yazar:: Ryota Otoshi, ve diğerleri
Baskı/Yayın Bilgisi: (2020-03-01)

Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study
Yazar:: Ian Pavord, ve diğerleri
Baskı/Yayın Bilgisi: (2023-04-01)